TY - JOUR
T1 - Drug resistance in glioblastoma
T2 - A mini review
AU - Haar, Catherine P.
AU - Hebbar, Preetha
AU - Wallace, Gerald C.
AU - Das, Arabinda
AU - Vandergrift, William A.
AU - Smith, Joshua A.
AU - Giglio, Pierre
AU - Patel, Sunil J.
AU - Ray, Swapan K.
AU - Banik, Naren L.
PY - 2012/6
Y1 - 2012/6
N2 - Glioblastoma multiforme (GBM) is recognized as the most common and lethal form of central nervous system cancer. Currently used surgical techniques, chemotherapeutic agents, and radiotherapy strategies have done very little in extending the life expectancies of patients diagnosed with GBM. The difficulty in treating this malignant disease lies both in its inherent complexity and numerous mechanisms of drug resistance. In this review, we summarize several of the primary mechanisms of drug resistance. We reviewed available published literature in the English language regarding drug resistance in glioblastoma. The reasons for drug resistance in glioblastoma include drug efflux, hypoxic areas of tumor cells, cancer stem cells, DNA damage repair, and miRNAs. Many potential therapies target these mechanisms, including a series of investigated alternative and plant-derived agents. Future research and clinical trials in glioblastoma patients should pursue combination of therapies to help combat drug resistance. The emerging new data on the potential of plantderived therapeutics should also be closely considered and further investigated.
AB - Glioblastoma multiforme (GBM) is recognized as the most common and lethal form of central nervous system cancer. Currently used surgical techniques, chemotherapeutic agents, and radiotherapy strategies have done very little in extending the life expectancies of patients diagnosed with GBM. The difficulty in treating this malignant disease lies both in its inherent complexity and numerous mechanisms of drug resistance. In this review, we summarize several of the primary mechanisms of drug resistance. We reviewed available published literature in the English language regarding drug resistance in glioblastoma. The reasons for drug resistance in glioblastoma include drug efflux, hypoxic areas of tumor cells, cancer stem cells, DNA damage repair, and miRNAs. Many potential therapies target these mechanisms, including a series of investigated alternative and plant-derived agents. Future research and clinical trials in glioblastoma patients should pursue combination of therapies to help combat drug resistance. The emerging new data on the potential of plantderived therapeutics should also be closely considered and further investigated.
KW - Alternative therapies
KW - Glioblastoma multiforme
KW - Glioblastoma stem cells
KW - Hypoxia-inducible factors
KW - MiRNAs
KW - Multidrug resistance
KW - P-Glycoprotein
UR - http://www.scopus.com/inward/record.url?scp=84862835220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862835220&partnerID=8YFLogxK
U2 - 10.1007/s11064-011-0701-1
DO - 10.1007/s11064-011-0701-1
M3 - Review article
C2 - 22228201
AN - SCOPUS:84862835220
SN - 0364-3190
VL - 37
SP - 1192
EP - 1200
JO - Neurochemical Research
JF - Neurochemical Research
IS - 6
ER -
